Longitudinal transcriptome analysis reveals a sustained differential gene expression signature in patients treated for acute Lyme disease

mBio

Volumn 7, Issue 1, 2016, Pages

  Bouquet, Jerome ^a   Soloski, Mark J ^b   Swei, Andrea ^c   Cheadle, Chris ^b   Federman, Scot ^a   Billaud, Jean Noel ^d   Rebman, Alison W ^b   Kabre, Beniwende ^a   Halpert, Richard ^d   Boorgula, Meher ^b   Aucott, John N ^b   Chiu, Charles Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

^d Qiagen Bioinformatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; TOLL LIKE RECEPTOR; TRANSCRIPTOME;

ACUTE DISEASE; ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CHRONIC DISEASE; CONTROLLED STUDY; DIFFERENTIALLY EXPRESSED GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LONGITUDINAL STUDY; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; BLOOD; BORRELIA BURGDORFERI; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; UNITED STATES;

ADULT; ANIMALS; BIOMARKERS; BORRELIA BURGDORFERI; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYME DISEASE; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; TRANSCRIPTOME; UNITED STATES;

EID: 84960153442     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00100-16     Document Type: Article

References (53)

1. Stanek G, Wormser GP, Gray J, Strle F. 2012. Lyme borreliosis. Lancet 379:461–473. http://dx.doi.org/10.1016/S0140-6736(11)60103-7.
2. Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, Mead PS. 2014. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis 59:676–681. http://dx.doi.org/10.1093/cid/ciu397.
3. Centers for Disease C, Prevention. 2013. Three sudden cardiac deaths associated with Lyme carditis—United States, November 2012-July 2013. MMWR Morb Mortal Wkly Rep 62:993–996. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6249a1.htm.
4. Marques A. 2008. Chronic Lyme disease: a review. Infect Dis Clin North Am 22:341–360, 7-8. http://dx.doi.org/10.1016/j.idc.2007.12.011.
5. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. 2009. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis 9:79. http://dx.doi.org/10.1186/1471-2334-9-79.
6. Aucott JN, Crowder LA, Kortte KB. 2013. Development of a foundation for a case definition of post-treatment Lyme disease syndrome. Int J Infect Dis 17:e443–e449. http://dx.doi.org/10.1016/j.ijid.2013.01.008.
7. Steere AC, Coburn J, Glickstein L. 2004. The emergence of Lyme disease. J Clin Invest 113:1093–1101. http://dx.doi.org/10.1172/JCI21681.
8. Sjöwall J, Fryland L, Nordberg M, Sjögren F, Garpmo U, Jansson C, Carlsson SA, Bergström S, Ernerudh J, Nyman D, Forsberg P, Ekerfelt C. 2011. Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans. PLoS One 6:e18220. http://dx.doi.org/10.1371/journal.pone.0018220.
9. Strle K, Stupica D, Drouin EE, Steere AC, Strle F. 2014. Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. Clin Infect Dis 58:372–380. http://dx.doi.org/10.1093/cid/cit735.
10. Moniuszko A, Czupryna P, Pancewicz S, Rutkowski K, Zajkowska O, Swierzbińska R, Grygorczuk S, Kondrusik M, Owłasiuk P, Zajkowska J. 2014. Evaluation of CXCL8, CXCL10, CXCL11, CXCL12 and CXCL13 in serum and cerebrospinal fluid of patients with neuroborreliosis. Immunol Lett 157:45–50. http://dx.doi.org/10.1016/j.imlet.2013.11.002.
11. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134. http://dx.doi.org/10.1086/508667.
12. Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN. 2014. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One 9:e93243. http://dx.doi.org/10.1371/journal.pone.0093243.
13. Molins CR, Ashton LV, Wormser GP, Hess AM, Delorey MJ, Mahapatra S, Schriefer ME, Belisle JT. 2015. Development of a metabolic biosignature for detection of early Lyme disease. Clin Infect Dis 60: 1767–1775. http://dx.doi.org/10.1093/cid/civ185.
14. Guo Y, Sheng Q, Li J, Ye F, Samuels DC, Shyr Y. 2013. Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. PLoS One 8:e71462. http://dx.doi.org/10.1371/journal.pone.0071462.
15. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP. 2013. Calculating sample size estimates for RNA sequencing data. J Comput Biol 20:970–978. http://dx.doi.org/10.1089/cmb.2012.0283.
16. Zhai Y, Franco LM, Atmar RL, Quarles JM, Arden N, Bucasas KL, Wells JM, Niño D, Wang X, Zapata GE, Shaw CA, Belmont JW, Couch RB. 2015. Host transcriptional response to influenza and other acute respiratory viral infections—a prospective cohort study. PLoS Pathog 11: e1004869. http://dx.doi.org/10.1371/journal.ppat.1004869.
17. Hou J, van Oord G, Groothuismink ZM, Claassen MA, Kreefft K, Zaaraoui-Boutahar F, van IJcken, WF, Osterhaus AD, Janssen HL, Andeweg AC, de Knegt RJ, Boonstra A. 2014. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J Virol 88:12254–12264. http://dx.doi.org/10.1128/JVI.00775-14.
18. Park SH, Moon Y. 2013. Integrated stress response-altered proinflammatory signals in mucosal immune-related cells. Immunopharmacol Immunotoxicol 35:205–214. http://dx.doi.org/10.3109/08923973.2012.742535.
19. Fontana MF, Banga S, Barry KC, Shen X, Tan Y, Luo ZQ, Vance RE. 2011. Secreted bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog 7:e1001289. http://dx.doi.org/10.1371/journal.ppat.1001289.
20. Embers ME, Ramamoorthy R, Philipp MT. 2004. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect 6:312–318. http://dx.doi.org/10.1016/j.micinf.2003.11.014.
21. Grolleau A, Kaplan MJ, Hanash SM, Beretta L, Richardson B. 2000. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 106:1561–1568. http://dx.doi.org/10.1172/JCI9352.
22. Okazaki T, Nishio A, Takeo M, Sakaguchi Y, Fukui T, Uchida K, Okazaki K. 2014. Inhibition of the dephosphorylation of eukaryotic initiation factor 2alpha ameliorates murine experimental colitis. Digestion 90:167–178. http://dx.doi.org/10.1159/000366414.
23. Myers TA, Kaushal D, Philipp MT. 2009. Microglia are mediators of Borrelia burgdorferi-induced apoptosis in SH-SY5Y neuronal cells. PLoS Pathog 5:e1000659. http://dx.doi.org/10.1371/journal.ppat.1000659.
24. Sharif O, Knapp S. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213:701–713. http://dx.doi.org/10.1016/j.imbio.2008.07.008.
25. Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, Singer M, Bellingan G. 2007. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 37:456–466. http://dx.doi.org/10.1002/eji.200636387.
26. Ruiz-Pacheco JA, Vivanco-Cid H, Izaguirre-Hernández IY, Estrada-García I, Arriaga-Pizano L, Chacón-Salinas R, Fonseca-Coronado S, Vaughan G, Tovar KR, Rivera-Osorio MP, Escobar-Gutiérrez A. 2014. TREM-1 modulation during early stages of dengue virus infection. Immunol Lett 158:183–188. http://dx.doi.org/10.1016/j.imlet.2014.01.003.
27. Oosting M, Buffen K, van der Meer JWM, Netea MG, Joosten LAB. 25 June 2014. Innate immunity networks during infection with Borrelia burgd or feri. Crit Rev Microbiol http://dx.doi.org/10.3109/1040841X.2014.929563.
28. McSweegan E. 2007. Anti-tumor necrosis factor-alpha treatment for Lyme borreliosis. J Infect Dis 196:1866–1867. http://dx.doi.org/10.1086/523828.
29. Steere AC, Angelis SM. 2006. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54: 3079–3086. http://dx.doi.org/10.1002/art.22131.
30. Racine R, Winslow GM. 2009. IgM in microbial infections: taken for granted? Immunol Lett 125:79–85. http://dx.doi.org/10.1016/j.imlet.2009.06.003.
31. Elsner RA, Hastey CJ, Olsen KJ, Baumgarth N. 2015. Suppression of long-lived humoral immunity following Borrelia burgdorferi infection. PLoS Pathog 11:e1004976. http://dx.doi.org/10.1371/journal.ppat.1004976.
32. Wang P, Hilton E. 2001. Contribution of HLA alleles in the regulation of antibody production in Lyme disease. Front Biosci 6:B10–B16. http://dx.doi.org/10.2741/Wang.
33. Crowley JT, Drouin EE, Pianta A, Strle K, Wang Q, Costello CE, Steere AC. 2015. A highly expressed human protein, apolipoprotein B-100, serves as an autoantigen in a subgroup of patients with Lyme disease. J Infect Dis 212:1841–1850. http://dx.doi.org/10.1093/infdis/jiv310.
34. Drouin EE, Seward RJ, Strle K, McHugh G, Katchar K, Londoño D, Yao C, Costello CE, Steere AC. 2013. A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum 65:186–196. http://dx.doi.org/10.1002/art.37732.
35. Pianta A, Drouin EE, Crowley JT, Arvikar S, Strle K, Costello CE, Steere AC. 2015. Annexin A2 is a target of autoimmune T and B cell responses associated with synovial fibroblast proliferation in patients with antibiotic-refractory Lyme arthritis. Clin Immunol 160:336–341. http://dx.doi.org/10.1016/j.clim.2015.07.005.
36. Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, Gaidici A, Wormser GP. 2003. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 115:91–96. http://dx.doi.org/10.1016/S0002-9343(03)00308-5.
37. Marques AR, Hornung RL, Dally L, Philipp MT. 2005. Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi. Clin Diagn Lab Immunol 12:1036–1040. http://dx.doi.org/10.1128/CDLI.12.9.1036-1040.2005.
38. Weissmann G. 2009. Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases. Bull NYU Hosp Jt Dis 67:251–253.
39. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH. 2011. Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from chronic fatigue syndrome. PLoS One 6:e17287. http://dx.doi.org/10.1371/journal.pone.0017287.
40. Centers for Disease Control and Prevention. 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 44:-590–591. http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm.
41. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. 2012. Differential gene and transcript expression analysis of RNA-Seq experiments with TopHat and cufflinks. Nat Protoc 7:562–578. http://dx.doi.org/10.1038/nprot.2012.016.
42. Law CW, Chen Y, Shi W, Smyth GK. 2014. voom: precision weights unlock linear model analysis tools for RNA-Seq read counts. Genome Biol 15:R29. http://dx.doi.org/10.1186/gb-2014-15-2-r29.
43. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. http://dx.doi.org/10.1093/nar/gkv007.
44. Dalman MR, Deeter A, Nimishakavi G, Duan ZH. 2012. Fold change and P value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 13(Suppl 2):S11. http://dx.doi.org/10.1186/1471-2105-13-S2-S11.
45. Krämer A, Green J, Pollard J, Jr., Tugendreich S. 2014. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30:523–530. http://dx.doi.org/10.1093/bioinformatics/btt703.
46. Borjesson DL, Kobayashi SD, Whitney AR, Voyich JM, Argue CM, Deleo FR. 2005. Insights into pathogen immune evasion mechanisms: Anaplasma phagocytophilum fails to induce an apoptosis differentiation program in human neutrophils. J Immunol 174:6364–6372. http://dx.doi.org/10.4049/jimmunol.174.10.6364.
47. Butchar JP, Cremer TJ, Clay CD, Gavrilin MA, Wewers MD, Marsh CB, Schlesinger LS, Tridandapani S. 2008. Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS One 3:e2924. http://dx.doi.org/10.1371/journal.pone.0002924.
48. Dame TM, Orenzoff BL, Palmer LE, Furie MB. 2007. IFN-gamma alters the response of Borrelia burgdorferi-activated endothelium to favor chronic inflammation. J Immunol 178:1172–1179. http://dx.doi.org/10.4049/jimmunol.178.2.1172.
49. Gow JW, Hagan S, Herzyk P, Cannon C, Behan PO, Chaudhuri A. 2009. A gene signature for post-infectious chronic fatigue syndrome. BMC Med Genomics 2:38. http://dx.doi.org/10.1186/1755-8794-2-38.
50. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, Piqueras B, Banchereau J, Palucka AK, Chaussabel D. 2007. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109:2066–2077. http://dx.doi.org/10.1182/blood-2006-02-002477.
51. Smeekens SP, Ng A, Kumar V, Johnson MD, Plantinga TS, van Diemen C, Arts P, Verwiel ET, Gresnigt MS, Fransen K, van Sommeren S, Oosting M, Cheng SC, Joosten LA, Hoischen A, Kullberg BJ, Scott WK, Perfect JR, van der Meer JW, Wijmenga C, Netea MG, Xavier RJ. 2013. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun 4:1342. http://dx.doi.org/10.1038/ncomms2343.
52. Teixeira VH, Olaso R, Martin-Magniette ML, Lasbleiz S, Jacq L, Oliveira CR, Hilliquin P, Gut I, Cornelis F, Petit-Teixeira E. 2009. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients. PLoS One 4:e6803. http://dx.doi.org/10.1371/journal.pone.0006803.
53. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193. http://dx.doi.org/10.1093/bioinformatics/19.2.185.